Emerging Advances in Gastrointestinal Cancers

We had the pleasure of speaking with John L. Marshall, MD, who discussed the evolving treatment landscape of HER2-targeted treatment strategies in colorectal cancer.

We had the pleasure of speaking with Ian Chau, MD, FRCP, who discussed the state of HER2-directed therapy in gastric/gastroesophageal cancer.

We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies.

We had the pleasure of speaking with Ryan Corcoran, MD, PhD, who discussed key takeaways regarding the use and investigation of HER2-targeted therapies in gastrointestinal malignancies.